Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of $270 million. PaxVax is majority owned by an affiliate of Cerberus Capital Management, L.P.

Read More

We want to offer you the best possible experience when using the OrganoPlate® for your experiments. This page contains training videos and protocols to get you started. For optimal user experience, we recommend you to follow these 5 steps before your first experiment:

Read More

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the Eversense® CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage of the Eversense System to its Medical Policy.

Read More

Venture Capital - Generating Opportunity in Montgomery County

Read More

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter reviewing the company's recent progress and clinical plans for the remainder of 2018 and 2019.

Read More

Meet RESI’s Network of Global Investors and Channel Partners

This fall, the Redefining Early Stage Investments Conference (RESI) will expand to include tech hubs and companies from the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA. RESI invites earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A, and series B funding.

As a client/partner of BioHealth Innovation and/or an early stage biohealth start-up in the BioHealth Capital Region, you can attend the RESI Boston September Conference at a reduced rate - $300 each ticket for the first 5 signups; each ticket valued at $1,295. 

RESI is a partnering vehicle for you to connect with global investors and strategic partners. You'll have an opportunity to showcase your technology and assets in a poster board format with our table in the exhibit hall. You can participate in partnering and networking all day, and explore the exhibit hall, investor panels and entrepreneur workshops.

Email BioHealth Innovation for the Discount Code and Register Now  

$300 for Tech Hub Members Includes:

• 1 Tech Hub Member (BioHealth Innovation Client / Partner) Ticket
• Present Your Technology in a Poster Board Format at BHI Table
• Company Datasheet Featured on Website and Newsletter
• All Day Access to Partnering, Networking, Panels and Workshops
• Continental Breakfast, Lunch, and Cocktail Reception
• All Registered Attendees Eligible to Apply to First Coast Innovation Challenge
  • Top 5 companies of the First Coast tech hub members will present their technology as a 10-minute pitch to a panel of early-stage investors.
  • Top 5 will be featured in Marketing Channels
  • It's FREE to Apply (Application Deadline:  8/17/18)

Read More

Maryland’s health tech startup ecosystem is at it again. Silver Spring-based startup which is named as Aziyo Biologics Inc. has raised an amount of $10 million from seven leading investors in a funding round which has been disclosed yesterday night in SEC filings.

Read More

Johns Hopkins University has been awarded up to $30 million to lead a consortium of three Mid-Atlantic universities that will work together on research projects with the National Institute of Standards and Technology.

Read More

Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today two key leadership promotions. Deborah Wild has been promoted from Vice President, Quality, Validation and Regulatory Affairs to Senior Vice President, Quality, Validation and Regulatory Affairs, and Ruby Hofmann has been promoted from Vice President, Human Resources and Organizational Development to Senior Vice President, Human Resources, and Organizational Development.

Read More

After a week of persistent rain throughout Maryland, it was blue skies and a perfect 85-degree summer afternoon that marked an important day for Paragon Bioservices and their 250+ employees. Dozens of those employees stepped off a charter bus from Baltimore to see the brand new 151,000 sq/ft GMP biomanufacturing facility near BWI for the first time. The wide-open parking lots and 200 yards between the nearest building presented a much different landscape than they were used to at their current UM BioPark location in the city. An afternoon picnic and site tour was organized as a celebration for their employees, who got to enjoy some delicious ole’ fashioned BBQ, music and games outside before a short welcome ceremony.

Read More

In the first such clinical trial in the United States, physician-scientists with the University of Maryland School of Medicine (UMSOM) are investigating the use of MRI-guided focused ultrasound to open the blood-brain barrier. The trial will be conducted with patients undergoing brain cancer surgery at the University of Maryland Medical Center (UMMC).

Read More

Recently, ClearMask received $25,000 in grant funding from the National Science Foundation (NSF) to support ClearMask's commercialization efforts. The funding is part of the NSF's National Innovation Corps (I-Corps) program that helps scientists and engineers move their technologies toward commercialization.

Read More

In last week’s Amplified column, I discussed how the traditional wisdom that small business pursues disruptive innovation and big business pursues sustaining innovation may no longer hold. This is especially likely in industries consisting of only a few large players that both have the resources to engage in disruptive innovation themselves and to raise the costs of entry to would-be competitors.

Read More